Tepezza

In January, 2021 the manufacturer of Tepezza announced a short-term supply disruption. Tepezza is now available again, and the Infusion Center of Pennsylvania is among the first centers in the nation to resume treatments.

The Infusion Center of Pennsylvania infuses Tepezza!

Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor used to treat Thyroid Eye Disease, an autoimmune disease characterized by proptosis (a condition where the eyes are pushed forward and bulge outward) leading to eye pain double vision and difficulty closing the eyelid.

ICPA participated in clinical trials of Tepezza and began administering the drug on the first day it was commercially available in March, 2020.

Need Help Paying for Tepezza?

Co-pay assistance may be available to qualifying patients. Visit the Tepezzza Co-pay Assistance website or contact us at (610) 495-6800.

More Information About Tepezza

Manufacturer:

Horizon Therapeutics

Class:

Growth hormone receptor blockers

What it treats:

    Thyroid Eye Disease (TED)

Prescribed by:

    Eye specialists

How administered:

IV infusion

Frequency:

    Once every 3 weeks for 8 doses

Length of infusion:

About 90 minutes

Related drugs:

None